Objective: To determine whether blood cells expressed α-Syn can differentiate Parkinson’s disease (PD) from healthy controls (HC). Methods: The concentrations of α-Syn were determined in samples of blood cell pellets using a quantitative Lipid-ELISA assay. In addition, the levels of total protein, hemoglobin, iron and H-ferritin were determined. The study includes samples from the Biofind cohort (n = 46 PD and 45 HC) and results were validated with an additional cohort (n = 35 PD and 28 HC). Results: A composite biomarker consisting of the concentrations of total α-Syn, proteinase-K resistant (PKres) α-Syn and phospho-Serine 129 α-Syn (PSer 129), is designed based on the analysis of the discovery BioFIND cohort. This composite biomarker differentiates a PD subgroup, presenting motor symptoms without dementia from a HC group, with a convincing accuracy, represented by an AUC = 0.81 (95% CI, 0.71 to 0.92). Closely similar results were obtained for the validation cohort, that is, AUC = 0.81, (95% CI, 0.70 to 0.94). Interpretation: Our results demonstrate the potential usefulness of blood cells expressed α-Syn as a biomarker for PD.
Bibliographical noteFunding Information:
Funding information Funding for this study was provided by Michael J. Fox Foundation, grant ID 11899. The authors thank Prof. Norman Grover for statistics consulting.
© 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.